×ž×“×™× ×”: טייוו×ן
שפה: ×¡×™× ×™×ª
מקור: 衛生ç¦åˆ©éƒ¨é£Ÿå“藥物管ç†ç½² (Ministry of Health and Welfare, Food And Drug Administration)
METRONIDAZOLE
賽諾è²è‚¡ä»½æœ‰é™å…¬å¸ å°åŒ—市信義å€æ¾ä»è·¯3號7樓 (97168356)
J01XD01
注射劑
METRONIDAZOLE (0832000300) 500MG
瓶è£;;å¡‘è† è»Ÿè¢‹è£
製 劑
é™ç”±é†«å¸«ä½¿ç”¨
BAXTER HEALTHCARE S.A. MONEEN ROAD CASTLEBAR CO. MAYO, IRELAND IE
metronidazole
å°ï¼ï¼¥ï¼´ï¼²ï¼¯ï¼®ï¼©ï¼¤ï¼¡ï¼ºï¼¯ï¼¬ï¼¥å…·æœ‰æ„Ÿå—性之åŽæ°§èŒæ‰€å¼•èµ·ä¹‹åš´é‡æ„ŸæŸ“åŠå°ï¼£ï¼¬ï¼©ï¼®ï¼¤ï¼¡ï¼ï¼¹ï¼£ï¼©ï¼®ã€€ï¼£ï¼¨ï¼¬ï¼¯ï¼²ï¼¡ï¼ï¼°ï¼¨ï¼¥ï¼®ï¼©ï¼£ï¼¯ï¼¬ã€€ï¼°ï¼¥ï¼®ï¼©ï¼£ï¼©ï¼¬ï¼¬ï¼©ï¼®å…·æŠ—藥性之易脆桿èŒï¼ˆï¼¢ï¼¡ï¼£ï¼´ï¼¥ï¼²ï¼©ï¼¯ï¼¤ï¼¥ï¼³ã€€ï¼¦ï¼¬ï¼¡ï¼§ï¼©ï¼¬ï¼©ï¼³ï¼‰æ‰€å¼•èµ·ä¹‹æ„ŸæŸ“有效
註銷日期: 2019/04/12; 註銷ç†ç”±: 自請註銷; 有效日期: 2019/09/16; 英文å“å: ANEGYN INJECTION 0.5%W/V
已註銷
1985-09-16
1/6 ANEGYN® _Metronidazole _ 0,5% W/V (100 ml) ANEGYN INJECTION 0.5% W/V 1. DESCRIPTION 1.1 ACTIVE INGREDIENT Metronidazole 1.2 PHARMACEUTICAL FORM A clean, bright, pale yellow sterile isotonic solution for intravenous infusion. 1.3 COMPOSITION Active ingredient: Metronidazole Excipients: Sodium phosphate, Citric acid anhydrous, Sodium chloride, Water for injections. 1.4 NATURE AND CONTENTS OF CONTAINER Anegyn Injection 0.5% w/v (100 ml) is available in Viaflex minibags. 2. INDICATIONS Anegyn is indicated in the prophylaxis and treatment of infections in which anaerobic bacteria have been identified or are suspected to be the cause. Anegyn is active against a wide range of pathogenic microorganisms notably species of _Bacteroides, _ _Fusobacteria, Clostridia, Eubacteria, _ anaerobic cocci and _Gardnerella vaginalis. _ It is indicated in: The prevention of postoperative infections due to anaerobic bacteria, particularly species of _Bacteroides _ and anaerobic Streptococci. The treatment of septicaemia, bacteraemia, peritonitis, brain abscess, necrotising pneumonia, osteomyelitis, puerperal sepsis, pelvic abscess, pelvic cellulitis, and postoperative wound infections from which pathogenic anaerobes have been isolated. 3. DOSAGE AND ADMINISTRATION Slow intravenous infusion of one 100 ml plastic bag (500 mg) over a period of 30 to 60 minutes. Oral medication should be substituted as soon as feasible. _ANAEROBIC INFECTIONS: _ Treatment for seven days should be satisfactory for most patients but, depending upon clinical and bacteriological assessments, the physician might decide to prolong treatment e.g. for the eradication of infection from sites which cannot be drained or are liable to endogenous recontamination by anaerobic pathogens from the gut, oropharynx or genital tract. _PROPHYLAXIS AGAINST ANAEROBIC INFECTION: _ Adults Usually, 500mg infused over 30 to 60 minutes immediately before surgery, followed by 2 infusions of 500mg at 8 hours and 16 hours after the initial dose. Children 2/6 20 to 30 mg/kg per day us ×§×¨× ×ת המסמך השל×